IDH2 Inhibition Using Enasidenib as Maintenance Therapy for IDH2-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation
Clinical trial NCT03515512 · COMPLETED
Trial details
- NCT number
- NCT03515512
- Sponsor
- Massachusetts General Hospital
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2018-07-17
- Primary completion
- 2021-12-31
- Enrollment
- 23
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.